Leiomyosarcoma future or investigational therapies
Following are some recently approved drugs in the treatment of the leimyosarcoma.
- Trabectedin was approved as a chemotherapy for leiomyosarcoma that cannot be operated or for the patients that previously underwent treatment with anthracycline. Trabectedin exerts its chemotherapeutic effect by alkylation and damages the DNA of cells, which prevents them from dividing, and causes them to die.[1]
- Pazopanib, an oral therapy for advanced leiomyosarcoma, is often combined with chemotherapy and/or radiation therapy.It works as a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis.[2]
- Currently, there are many investigational studies are going on to identify other agents that may prove useful in the treatment of Leiomyosarcoma.Clinical trials are testing new drugs to see if they're safe and if they work.[3]
References
- ↑ Brodowicz T (2014) Trabectedin in soft tissue sarcomas. Future Oncol 10 (8 Suppl):s1-5. DOI:10.2217/fon.14.117 PMID: 25048043
- ↑ van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG et al. (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 (9829):1879-86. DOI:10.1016/S0140-6736(12)60651-5 PMID: 22595799
- ↑ Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C et al. (2015) Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol 16 (4):457-64. DOI:10.1016/S1470-2045(15)70070-7 PMID: 25795402